Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential

References

• Modiano JF, Breen M, Burnett RC, et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res 2005;65:5654–5661.
   PubMed Web of Science ®Google Scholar
• Chun R. Lymphoma: which chemotherapy protocol and why?Top Companion Anim Med 2009;24:157–162.
   PubMed Web of Science ®Google Scholar
• Modiano JF, Breen M, Valli VE, et al. Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma. Leukemia 2007;21:184–187.
   PubMed Web of Science ®Google Scholar
• Frantz AM, Sarver AL, Ito D, et al. Molecular profiling reveals prognostically significant subtypes of canine lymphoma. Vet Pathol 2013;50:693–703.
   PubMed Web of Science ®Google Scholar
• Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704–709.
   PubMed Web of Science ®Google Scholar
• MacDonald VS, Thamm DH, Kurzman ID, et al. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?J Vet Intern Med 2005;19:732–736.
   PubMed Web of Science ®Google Scholar
• Vail DM, Pinkerton MM, Young KM. Canine lymphoma and lymphoid leukemia. In: Withrow SJ, Vail DM, Page RL, editors. Withrow and MacEwen's small animal clinical oncology. 5th ed. St. Louis: Saunders; 2012. pp 608–638.
   Google Scholar
• Traullé C, Coiffier BB. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Future Oncol 2005; 1:297–306.
   PubMedGoogle Scholar
• Jubala CM, Wojcieszyn JW, Valli VEO, et al. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. 2005;42:468–476.
   Google Scholar
• Impellizeri JA, Howell K, McKeever KP, et al. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation. Vet J 2006;171:556–558.
   PubMed Web of Science ®Google Scholar
• Rütgen BC, Hammer SE, Gerner W, et al. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res 2010;34:932–938.
   PubMed Web of Science ®Google Scholar
• Harlow E, Lane D. Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1988. pp 139–318.
   Google Scholar
• Ito D, Endicott MM, Jubala CM, et al. A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphoma. J Vet Intern Med 2011;25:890–896.
   PubMed Web of Science ®Google Scholar
• Ito D, Frantz AM, Williams C, et al. CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitropreclinical studies with primary B-cell malignancies. Leuk Lymphoma 2012;53:1390–1398.
   PubMed Web of Science ®Google Scholar
• Ernst JA, Li H, Kim HS, et al. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005;44:15150–15158.
   PubMed Web of Science ®Google Scholar
• Binder M, Otto F, Mertelsmann R, et al. The epitope recognized by rituximab. Blood 2006;108:1975–1978.
   PubMed Web of Science ®Google Scholar
• Perosa F, Favoino E, Caragnano MA, et al. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006;107:1070–1077.
   PubMedGoogle Scholar
• Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem 2007;282: 15073–15080.
   PubMed Web of Science ®Google Scholar
• Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450–454.
   PubMedGoogle Scholar
• Hultin LE, Hausner MA, Hultin PM, et al. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 1993;14:196–204.
   PubMedGoogle Scholar
• Buckner CL, Christiansen LR, Bourgeois D, et al. CD20 positive T-cell lymphoma/leukemia: a rare entity with potential diagnostic pitfalls. Ann Clin Lab Sci 2007;37:263–267.
   PubMed Web of Science ®Google Scholar
• Dotan E, Aggarwal C, Smith MR. Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. 2010;35:148–157.
   Google Scholar
• Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95:135–143.
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793–1800.
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362–371.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115–123.
   PubMed Web of Science ®Google Scholar